GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Mineralys Therapeutics
The stock of Mineralys, a biotech company focused on treating hypertension, reflects the potential of its leading drug. The price chart is a classic biotech story, with the price determined by expectations of clinical trial results.
Share prices of companies in the market segment - Heart
Mineralys is a biotech company focused on treating hypertension. We classify it as a cardiology company, and the chart below reflects general trends and investor sentiment in this biotech sector.
Broad Market Index - GURU.Markets
Mineralys Therapeutics is a biopharmaceutical company developing drugs to treat conditions associated with abnormally high aldosterone levels. Its focus on cardiology makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Mineralys compares to it.
Change in the price of a company, segment, and market as a whole per day
MLYS - Daily change in the company's share price Mineralys Therapeutics
For Mineralys Therapeutics, a biopharmaceutical company, change_co is a measure of the sector's inherently high volatility. Each daily change reflects sensitivity to news about clinical trials of its drugs. This metric isn't just noise, but a critical component of the models on System.GURU.Markets that assess risk in innovative medicine.
Daily change in the price of a set of shares in a market segment - Heart
Mineralys Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparing it to MLYS, which depends on the results of clinical trials of its heart disease drugs, helps assess it as a high-risk asset compared to more diversified companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Mineralys Therapeutics is a biopharmaceutical company developing drugs to treat hypertension. Cardiology is a risky area of research. The chart below illustrates the high volatility typical of the biotech sector, reflecting the stakes associated with Mineralys' developments.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Mineralys Therapeutics
Mineralys is a biotech company specializing in the treatment of cardiovascular diseases. Given the prevalence of these diseases, its developments are attracting considerable attention. Its shares are volatile and dependent on research progress, contributing to market dynamics.
Annual dynamics of market capitalization of the market segment - Heart
Mineralys Therapeutics, Inc. is a clinical-stage biotech company developing drugs to treat hypertension. Its stock price is entirely dependent on clinical trial results. The chart reflects the high risks and potential for a breakthrough in the treatment of one of the most common diseases.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Mineralys Therapeutics is a clinical-stage biotech whose value reflects the promise of new drugs. Its shares are extremely volatile and completely disconnected from economic cycles. The company's chart isn't about business, but about binary events: the success or failure of clinical trials.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Mineralys Therapeutics
Mineralys, a biopharmaceutical company developing drugs to treat hypertension, has sharp monthly fluctuations reflecting news about clinical trials of its lead candidate, which is typical for biotech companies in the development stage.
Monthly dynamics of market capitalization of the market segment - Heart
Mineralys Therapeutics is a biopharmaceutical company developing targeted therapies for hypertension and related cardiovascular diseases. Its sector dynamics, shown in the chart, reflect the risks of clinical trials. This allows us to assess how the potential of its drug for the treatment of difficult-to-control hypertension affects investor perceptions of the company.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Mineralys Therapeutics is a biopharmaceutical company developing drugs to treat hypertension. Cardiovascular disease is a huge market. The chart below shows how much the stock's performance was out of sync with the broader market, moving in sync with clinical trial news rather than macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Mineralys Therapeutics
Shares of Mineralys Therapeutics, a clinical-stage biopharmaceutical company, exhibit high volatility. Weekly price movements depend entirely on news about the progress of clinical trials of their cardiovascular drugs. The chart below illustrates how investor expectations for the biotech sector fluctuate from week to week.
Weekly dynamics of market capitalization of the market segment - Heart
How does Mineralys Therapeutics' performance compare to the broader biotech sector? This chart compares the company's weekly share price movements, driven by clinical trial news, with the overall trend. This helps us understand whether the stock's movement is the result of a unique development in cardiac treatment or a reflection of general sentiment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Mineralys Therapeutics is a clinical-stage biotech focused on treating hypertension. This chart shows how its weekly performance is independent of the broader market. Its stock price movements are driven solely by news about the progress of its drug candidates' clinical trials.
Market capitalization of the company, segment and market as a whole
MLYS - Market capitalization of the company Mineralys Therapeutics
The Mineralys Therapeutics valuation chart reflects investors' hopes for its drug for the treatment of uncontrolled hypertension. As a company in clinical development, its market cap is entirely dependent on the success of trials and future regulatory approval. Its price dynamics reflect every step of this risky path to market.
MLYS - Share of the company's market capitalization Mineralys Therapeutics within the market segment - Heart
Mineralys Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of hypertension and cardiovascular diseases. Its share of its sector market cap reflects the large potential market for its candidates. The chart shows how investors view the company's clinical development prospects in one of the most common areas of medicine.
Market capitalization of the market segment - Heart
The chart below shows the total market capitalization of biotech companies focused on treating cardiovascular diseases. Mineralys Therapeutics is a niche player with a targeted approach. The diagram illustrates the scale and risks of the sector, where the company is trying to solve the problem of uncontrolled hypertension.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart depicts the market valuation of a potential breakthrough in hypertension treatment. Mineralys Therapeutics' market capitalization is not based on current sales, but on investors' faith in the success of its new drug. The line shows how the hope for a solution to one of the most common health problems shapes its share of the global economy.
Book value capitalization of the company, segment and market as a whole
MLYS - Book value capitalization of the company Mineralys Therapeutics
The book value of clinical-stage Mineralys Therapeutics is derived from its scientific potential. The chart below reflects the financial valuation of its intellectual property and cash reserves, which are dedicated to developing hypertension drugs. The dynamics illustrate how the company invests in research, building its core asset.
MLYS - Share of the company's book capitalization Mineralys Therapeutics within the market segment - Heart
For Mineralys Therapeutics, a young biotech company in clinical development, its tangible assets are limited to laboratories and offices. The chart shows its modest share of physical infrastructure, emphasizing that its primary value lies in its intellectual property, not its manufacturing facilities.
Market segment balance sheet capitalization - Heart
Mineralys Therapeutics is a clinical-stage biotech company. Its value is created in labs, not factories, making it inherently "lightweight." Its core assets are patents and data. The chart below shows how much the pharmaceutical industry relies on tangible assets versus intellectual property.
Book value of all companies included in the broad market index - GURU.Markets
Mineralys Therapeutics' balance sheet represents net worth, focused on a single objective: developing a new class of drugs for the treatment of hypertension. The book value chart reflects the financial resources concentrated in this important area of cardiology and serves as a gauge of investor expectations.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biotech company developing a treatment for hypertension. It has no revenue and almost no assets other than cash. Its entire market capitalization is a bet by investors on the success of clinical trials for a single drug. The graph is a pure estimate of the probability of future scientific and commercial success.
Market to book capitalization ratio in a market segment - Heart
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on treating hypertension. It has virtually no tangible assets. Its entire market valuation is a bet investors place on the success of its single drug candidate. The chart shows this enormous premium for the hope of a future blockbuster.
Market to book capitalization ratio for the market as a whole
Mineralys Therapeutics is a clinical-stage biotech developing drugs to treat hypertension. The chart shows how the market values this scientific idea with a huge potential market. Its market capitalization is not tied to tangible assets, but rather reflects investors' bet that its research will lead to the next blockbuster in cardiology.
Debts of the company, segment and market as a whole
MLYS - Company debts Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on treating hypertension-related conditions. Financing expensive clinical trials is a key challenge. This chart shows how the company is raising capital, including debt, to advance its development toward regulatory approval.
Market segment debts - Heart
Mineralys Therapeutics is a clinical-stage biopharmaceutical company specializing in the treatment of diseases associated with abnormally high aldosterone levels. Such companies are typically financed through equity rather than debt. The chart illustrates the general norms for the pharmaceutical sector, highlighting the high-risk funding model for R&D startups.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biotech developing drugs to treat blood pressure-related conditions. Until its product reaches market, the company has no revenue and requires external funding. This chart shows how it uses capital, including debt, to conduct expensive research.
Market segment debt to market segment book capitalization - Heart
Mineralys Therapeutics is a biopharmaceutical company focused on developing drugs to treat heart disease. This chart compares the debt required to fund clinical trials to the overall market capitalization of the entire cardiac sector. It demonstrates the company's investment in the fight against heart disease.
Debt to book value of all companies in the market
Mineralys Therapeutics is an early-stage biotech company. This chart compares its low debt to the total market capitalization of the entire economy. It shows how insignificant its current financial footprint is, but any growth would indicate aggressive plans to raise capital to fund breakthrough research.
P/E of the company, segment and market as a whole
P/E - Mineralys Therapeutics
This metric for Mineralys Therapeutics, a clinical-stage biotech company specializing in the treatment of heart disease, reflects future expectations. Its value is determined not by current profits, but by investors' faith in the potential of its developments to combat hypertension. The chart represents a valuation of scientific breakthroughs, not financial results.
P/E of the market segment - Heart
This metric represents the average valuation for the biotech sector in which Mineralys Therapeutics operates. In this industry, which is full of research-stage companies, the average earnings valuation is often uninformative. However, it does reflect the overall level of investor optimism regarding scientific breakthroughs and serves as a benchmark for understanding the company's value.
P/E of the market as a whole
Mineralys Therapeutics is a biopharmaceutical company focused on developing treatments for conditions associated with abnormally high aldosterone levels, such as hypertension. The company is targeting a huge market. This risk-attitude chart helps understand how investors evaluate biotech startups.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat hypertension. This chart reflects investor expectations regarding the success of clinical trials and the potential market size for its future drug. It is a speculative estimate of the likelihood of a scientific breakthrough in the treatment of a common disease.
%20P%2FE%20Mineralys%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Mineralys-Therapeutics&v=1772489381631 "Chart of the company's future (projected) P/E Mineralys Therapeutics")
Future (projected) P/E of the market segment - Heart
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel treatments for conditions associated with abnormally elevated aldosterone levels, such as uncontrolled hypertension. This chart illustrates overall market sentiment toward the biotech sector, helping to assess the potential of Mineralys' niche strategy.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Heart&v=1772489381632 "Future (projected) P/E graph of the market segment - Heart")
Future (projected) P/E of the market as a whole
Mineralys Therapeutics is a clinical-stage biotechnology company developing a drug for the treatment of uncontrolled hypertension. Its valuation is based solely on the potential of this drug. The company's valuation is not tied to overall market forecasts but depends on the results of future studies.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772489381632 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of conditions associated with abnormally high aldosterone levels, such as hypertension. Its financial metrics currently reflect research expenditures. This chart shows the investment in bringing a new drug to market.
Profit of companies in the market segment - Heart
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat conditions associated with abnormally elevated aldosterone levels, such as hypertension. This chart shows the overall profitability of the cardiology segment. The company does not yet have revenue, and its R&D costs impact current overall profitability, but its success could change the standard of care.
Overall market profit
Mineralys Therapeutics is a biopharmaceutical company developing drugs for the treatment of hypertension-related conditions. Its potential lies in the success of clinical trials and the demand for new treatments. Against the backdrop of general economic cycles, as reflected in this chart, Mineralys creates value through scientific innovation in cardiology.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for conditions associated with abnormally high aldosterone levels, such as hypertension. This chart reflects analysts' earnings expectations, based on the potential success of clinical trials and entry into the large cardiac drug market.
%20profit%20of%20the%20company%20Mineralys%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Mineralys-Therapeutics&v=1772489381635 "Graph of future (projected) profit of the company Mineralys Therapeutics")
Future (predicted) profit of companies in the market segment - Heart
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for diseases associated with abnormally elevated aldosterone levels. This chart shows revenue projections for the cardiology segment. It reflects expectations for new treatments for hypertension and cardiovascular disease.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Heart&v=1772489381635 "Graph of future (predicted) profits of companies in a market segment - Heart")
Future (predicted) profit of the market as a whole
Mineralys Therapeutics is a biopharmaceutical company focused on treating diseases associated with abnormally high blood pressure. Its success depends on clinical breakthroughs. At the same time, the overall profit forecast reflected here provides an investment backdrop. Market optimism facilitates raising the funds needed for final-stage research and drug commercialization.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772489381637 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biotech developing drugs for the treatment of hypertension. Without stable sales, P/S ratio is not yet a key metric. However, the chart will be crucial after the product launch to determine how the market evaluates initial revenues and the future commercial potential of its innovative approach.
P/S market segment - Heart
Mineralys Therapeutics is a clinical-stage biotech focused on developing treatments for hypertension and other cardiovascular diseases. Its valuation is based entirely on the prospects of its future drug. The chart below shows how high investor expectations for its developments are compared to other cardiac biotechs.
P/S of the market as a whole
Mineralys Therapeutics is a clinical-stage biotechnology company developing drugs for the treatment of hypertension. The company currently has no revenue, and its valuation is based on the potential of its future drug. This chart, reflecting the valuation of companies with actual revenue, clearly demonstrates that Mineralys' valuation is a bet on future scientific and commercial success.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biotech company developing a drug to treat hypertension. Its valuation is based on the potential of this drug. This chart fully reflects investor expectations for future revenue from the commercialization of this product, which has the potential to capture a significant share of the vast hypertension treatment market.
%20P%2FS%20Mineralys%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Mineralys-Therapeutics&v=1772489381640 "The graph of the company's future (projected) P/S Mineralys Therapeutics")
Future (projected) P/S of the market segment - Heart
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat conditions associated with abnormally high aldosterone levels, including hypertension. This chart shows how the market views the future potential of its targeted therapy compared to other companies in the cardiology sector, reflecting confidence in its scientific approach.
%20P%2FS%20market%20segment%20graph%20-%20Heart&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Heart&v=1772489381643 "Future (projected) P/S market segment graph - Heart")
Future (projected) P/S of the market as a whole
Mineralys Therapeutics is a biopharmaceutical company focused on developing drugs to treat hypertension. It is targeting a huge market with an unmet need. This chart reflects general expectations for future sales, and MLYS shows how investors assess the potential of companies to offer new solutions for the most common diseases.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772489381644 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing drugs to treat conditions associated with abnormally elevated aldosterone levels, such as hypertension. The chart shows its revenue, which at this stage may be zero or may consist of collaboration fees rather than sales.
Sales of companies in the market segment - Heart
Mineralys Therapeutics is a biotech company focused on treating hypertension-related heart disease. At this stage, its revenue likely comes from partnerships. This chart allows investors to see financial support from partners, which is an indicator of confidence in its scientific developments.
Overall market sales
Mineralys Therapeutics is a biopharmaceutical company focused on treating blood pressure-related conditions. Its potential depends on the success of clinical trials and the commercialization of its drugs. The general economic cycles visible in this chart do not directly impact the scientific progress and medical needs that drive Mineralys.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing drugs for the treatment of hypertension. Its revenue forecast is based entirely on the expected future success of its lead candidate. This chart shows analysts' speculative estimates of the approval probability and commercial potential of the new drug.
%20sales%20of%20the%20company%20Mineralys%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Mineralys-Therapeutics&v=1772489381647 "Schedule of future (projected) sales of the company Mineralys Therapeutics")
Future (projected) sales of companies in the market segment - Heart
Mineralys Therapeutics is a biopharmaceutical company developing drugs to treat hypertension and cardiovascular diseases. This chart shows projected revenue for the cardiology segment. It provides an indication of the size of the market analysts believe for new treatments, which is critical to the commercial potential of Mineralys' developments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Heart&v=1772489381647 "Schedule of future (projected) sales of companies in the market segment - Heart")
Future (projected) sales of the market as a whole
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of hypertension. While there is no direct correlation with demand, the overall economic situation, reflected in the chart, is critical. It influences investor sentiment and their willingness to finance long-term and risky biotech projects, which is fundamental to the company's survival.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772489381648 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat hypertension. This chart reflects its current focus on research. It doesn't show profit, but rather the efficiency of investing capital into clinical trials, the success of which determines the company's entire future value.
Market segment marginality - Heart
Mineralys Therapeutics is a biopharmaceutical company focused on developing new treatments for hypertension. This chart currently reflects its potential. If its drugs are commercially successful, margins above the industry average will demonstrate the value of its innovations for millions of patients and the healthcare system.
Market marginality as a whole
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat hypertension. Its future depends on successful clinical trials and regulatory approval. This chart shows current market profitability, while Mineralys' entire value is a bet on a future breakthrough in the treatment of this very common disease.
Employees in the company, segment and market as a whole
Number of employees in the company Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biotechnology company developing drugs for the treatment of hypertension. Its current staff consists primarily of scientists and clinical trial specialists. The team's growth, visible in this chart, signals the lead candidate's progress through the clinical trial phases.
Share of the company's employees Mineralys Therapeutics within the market segment - Heart
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for hypertension and cardiovascular disease. This chart reflects the concentration of scientific talent. It shows the proportion of cardiologists and researchers working on new approaches to blood pressure control that are part of this focused company.
Number of employees in the market segment - Heart
Mineralys Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of hypertension and cardiovascular diseases. This chart illustrates employment in the cardiology sector. The growing number of specialists in this field indicates high demand for new treatments, creating a favorable environment for Mineralys' clinical trials.
Number of employees in the market as a whole
Mineralys Therapeutics is a biopharmaceutical company focused on treating blood pressure-related conditions. The growth of its small but highly skilled team of scientists reflects progress in developing new treatments for common diseases. It's an example of how science is creating the jobs of the future in healthcare.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Mineralys Therapeutics (MLYS)
Mineralys Therapeutics is a clinical-stage biotech company developing drugs for hypertension. Their entire current value is derived from investor expectations regarding the success of their developments. This chart clearly demonstrates how the market values pure intellectual capital: a potential blockbuster developed by a small team of scientists yields a huge market capitalization.
%20of%20the%20company%20Mineralys%20Therapeutics%20(MLYS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Mineralys-Therapeutics-MLYS&v=1772489381657 "Chart of market capitalization per employee (in thousands of dollars) of the company Mineralys Therapeutics (MLYS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Heart
Mineralys is a clinical-stage biotech company developing a new drug for the treatment of hypertension. Like other R&D companies, its value depends entirely on the success of clinical trials. This chart shows the industry average, helping to assess the market value investors attribute to the potential of this research team.
%20by%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Heart&v=1772489381658 "Market capitalization per employee (in thousands of dollars) by market segment - Heart")
Market capitalization per employee (in thousands of dollars) for the overall market
Mineralys Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of hypertension treatments. The company's entire value is based on the success of its single lead drug. This chart reflects investors' faith that a small team of scientists will be able to bring their research to commercial success.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772489381658 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Mineralys Therapeutics (MLYS)
Mineralys Therapeutics is a clinical-stage biotech company developing drugs for the treatment of hypertension and related conditions. The company's business is purely R&D. This graph, in negative territory, shows the amount of investment burned through each scientist and employee during expensive clinical trials of a new drug.
%20Chart%20Mineralys%20Therapeutics%20(MLYS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Mineralys-Therapeutics-MLYS&v=1772489381659 "Company Profit Per Employee (in thousands of dollars) Chart Mineralys Therapeutics (MLYS)")
Profit per employee (in thousands of dollars) in the market segment - Heart
Mineralys Therapeutics is a clinical-stage biotech company developing a drug to treat hypertension (high blood pressure). This chart shows the benchmark for the "Biotech" sector. In this sector, the benchmark for profit per employee is typically *deeply negative*. Companies are burning through money on R&D (clinical trials).
%20in%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Heart&v=1772489381660 "Chart of profit per employee (in thousands of dollars) in the market segment - Heart")
Profit per employee (in thousands of dollars) for the market as a whole
Mineralys Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of uncontrolled hypertension (high blood pressure). This R&D activity is in a very common field. This chart, showing the average market profitability per employee, helps us understand how the cardiology R&D sector compares to average efficiency.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772489381660 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Mineralys Therapeutics (MLYS)
Mineralys Therapeutics is an early-stage biotech company. In this graph, revenue per employee is likely zero or very low, which is typical for the sector. It reflects scientific potential rather than current operations. Success in clinical trials could lead to explosive growth in this metric.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Mineralys-Therapeutics-MLYS&v=1772489381662 "Sales chart per company employee Mineralys Therapeutics (MLYS)")
Sales per employee in the market segment - Heart
Mineralys Therapeutics is a clinical-stage biotech company focused on treating hypertension. Revenue is currently minimal. This chart shows the average revenue per employee in the segment, which serves as a benchmark for commercial pharmaceutical companies. It provides context for assessing the effectiveness of Mineralys' staff within the industry.
Sales per employee for the market as a whole
Mineralys Therapeutics (MLYS) is a clinical-stage biotech company specializing in the treatment of hypertension. Like other biotechs without a product on the market (CRNX, CNTA), this metric is currently negative or close to zero. It merely reflects the rate of burn on R&D staff. Investors are anticipating clinical successes, which will lead to explosive growth in this graph in the future.
Short shares by company, segment and market as a whole
Shares shorted by company Mineralys Therapeutics (MLYS)
Mineralys Therapeutics is a biotech company focused on treating hypertension (high blood pressure). It's a huge but highly competitive market. This chart illustrates investor skepticism. The bears are betting that their drug candidate won't be able to demonstrate its superiority over existing, low-cost generics, making it commercially unsuccessful.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Mineralys-Therapeutics-MLYS&v=1772489381665 "Short Shares Chart for the Company Mineralys Therapeutics (MLYS)")
Shares shorted by market segment - Heart
Mineralys Therapeutics is a clinical-stage biotech developing drugs to treat hypertension. This chart highlights the pessimism in the biotech sector. The high level of short positions across the industry reflects investors' general reluctance to take risks in companies that don't yet have revenue and concerns about the intense competition in the blood pressure drug market.
Shares shorted by the overall market
Mineralys Therapeutics (MLYS) is a clinical-stage biotech developing drugs to treat hypertension. It's a huge market. However, this chart highlights general market fear. When investors are scared, they avoid stocks of companies that don't yet have revenue. MLYS needs capital for research, and the risk-off sentiment (as reflected in the chart) makes it difficult to attract.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Mineralys Therapeutics (MLYS)
Mineralys Therapeutics is a clinical-stage biotech company. Its survival is entirely dependent on access to capital markets. This chart for MLYS can soar above 70 on positive trial data. Oversold territory (<30) often reflects failure or general risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Mineralys-Therapeutics-MLYS&v=1772489381668 "RSI 14 indicator chart for the company's stock Mineralys Therapeutics (MLYS)")
RSI 14 Market Segment - Heart
Mineralys Therapeutics is a biotech company focused on developing drugs to treat aldosterone-related conditions, primarily uncontrolled hypertension. This chart measures the overall momentum in the cardiac biotech sector. It helps determine whether the entire segment is overheated by expectations of new breakthroughs.
RSI 14 for the overall market
Mineralys Therapeutics (MLYS) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MLYS (Mineralys Therapeutics)
Mineralys Therapeutics is a clinical-stage biotech company developing drugs for the treatment of hypertension (high blood pressure). This chart shows the average analyst consensus. Their forecasts are based entirely on the estimated likelihood of clinical trial success for their lead candidate and the potential market size for this new class of hypertension drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MLYS-Mineralys-Therapeutics&v=1772489381674 "A chart showing analyst consensus forecasts for the expected stock price. MLYS (Mineralys Therapeutics)")
The difference between the consensus estimate and the actual stock price MLYS (Mineralys Therapeutics)
Mineralys Therapeutics is a clinical-stage biotech focused on a single product (Lorundrostat) for the treatment of uncontrolled hypertension (high blood pressure). This chart reflects analysts' high expectations for their clinical data and the potential size of this massive market. It also shows the gap between their target price and the current price.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MLYS-Mineralys-Therapeutics&v=1772489381676 "A chart showing the difference between the consensus forecast and the actual stock price. MLYS (Mineralys Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Heart
Mineralys is a biotech company targeting a huge but complex market: the treatment of *uncontrolled* hypertension (high blood pressure) that is not treatable with conventional medications. This chart shows analysts' overall expectations for the cardiac drug sector, reflecting whether experts believe a breakthrough is possible in this market.
Analysts' consensus forecast for the overall market share price
Mineralys Therapeutics (MLYS) is a biopharmaceutical company focused on treating hypertension (high blood pressure). They are developing a new drug for patients who are not responding to existing medications. This chart shows the overall risk appetite, reflecting the market's willingness to fund research in such widespread but complex areas of medicine.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biotech focused on one goal: developing a new drug (lorundrostat) for the treatment of uncontrolled hypertension. This chart represents pure R&D investment. It likely reflects investors' faith in successful clinical trials and the enormous market potential of their drug, rather than revenue.
AKIMA Market Segment Index - Heart
Mineralys (MLYS) is a clinical-stage biotech focused on hypertension (high blood pressure); the company is developing a targeted drug (Lorundrostat) for patients who are not responding to older medications. This summary metric evaluates R&D. The graph shows the average value for the segment. This benchmark: how does MLYS's niche (resistant hypertension) R&D focus differentiate it from the average pharma company?
The AKIM Index for the overall market
Mineralys is a clinical-stage biotech focused on cardiovascular disease, specifically uncontrolled hypertension. It's a high-risk scientific bet. This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for funding such companies.
